8 studies found for:    rucaparib
Show Display Options
Rank Status Study
1 Recruiting A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
Conditions: Ovarian Cancer;   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Intervention: Drug: Oral rucaparib
2 Recruiting A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Conditions: Pancreatic Cancer;   Pancreatic Ductal Adenocarcinoma
Intervention: Drug: Rucaparib
3 Recruiting A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: Rucaparib;   Drug: Placebo
4 Recruiting A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Intervention: Drug: Rucaparib
5 Active, not recruiting A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens
Condition: Advanced Solid Tumors
Interventions: Drug: PF-01367338;   Drug: Carboplatin
6 Active, not recruiting Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
Conditions: brca1 Mutation Carrier;   brca2 Mutation Carrier;   Breast Cancer;   Ovarian Cancer
Interventions: Drug: rucaparib (CO-338; formally AG-014699 or PF-01367338);   Genetic: protein expression analysis;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study
7 Active, not recruiting PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Condition: Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Rucaparib
8 Withdrawn A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)
Conditions: Diabetes Mellitus;   Diabetic Retinopathy
Intervention: Drug: AG-014699

Indicates status has not been verified in more than two years